Advertisement
Screener

ARDELYX, INC. (ARDX) Overview

ARDELYX, INC. (ARDX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.07; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.15; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.00; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.08; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$2.73$3.42$4.28$5.36$6.70$8.392025-11-062026-11-06$0.48$0.89$1.64$3.02$5.56$10.232021-11-082026-11-06$0.48$0.99$2.00$4.07$8.29$16.852016-11-072026-11-06$0.48$1.14$2.67$6.27$14.71$34.532014-06-192026-11-06$0.48$1.14$2.67$6.27$14.71$34.532014-06-192026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$2.88
Previous close
$3.39
Change
-$0.52
Change (%)
-15.19%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ARDX
-41.85%
S&P 500
(m)

1 year

ARDX
-39.79%
S&P 500
(m)

3 years

ARDX
-16.91%
S&P 500
(m)

5 years

ARDX
+164.84%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.07

-0.25-0.14-0.040.070.1831 Mar 2025: estimate (m); actual -0.1731 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.0830 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.0030 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.1531 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.07(m)(m)
1 Jan 202631 Mar 2026(m)-0.15(m)(m)
1 Jul 202530 Sept 2025(m)0.00(m)(m)
1 Apr 202530 Jun 2025(m)-0.08(m)(m)
1 Jan 202531 Mar 2025(m)-0.17(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.26

-1.60-1.20-0.80-0.390.0131 Dec 2021: estimate (m); actual -1.5231 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.4231 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.3031 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.1731 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.2631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.26(m)(m)
1 Jan 202431 Dec 2024(m)-0.17(m)(m)
1 Jan 202331 Dec 2023(m)-0.30(m)(m)
1 Jan 202231 Dec 2022(m)-0.42(m)(m)
1 Jan 202131 Dec 2021(m)-1.52(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 120.88M ■ Earnings -16.72M — Profit margin -13.83%

-57.14M-40.8%10.16M-27.1%77.45M-13.4%144.75M0.4%30 Sept 2025: revenue 110.33M; earnings -0.97M; profit margin -0.88%30 Sept 202531 Dec 2025: revenue 125.22M*; earnings -0.81M*; profit margin -0.65%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 94.47M; earnings -37.60M; profit margin -39.81%31 Mar 202630 Jun 2026: revenue 120.88M; earnings -16.72M; profit margin -13.83%30 Jun 2026

31 Dec 2025 ■ Revenue 407.32M ■ Earnings -62.00M — Profit margin -15.22%

-123.92M-129.5%72.13M-89.9%268.19M-50.3%464.24M-10.7%31 Dec 2022: revenue 52.16M; earnings -67.00M; profit margin -128.46%31 Dec 202231 Dec 2023: revenue 124.46M; earnings -66.00M; profit margin -53.03%31 Dec 202331 Dec 2024: revenue 333.62M; earnings -39.00M; profit margin -11.69%31 Dec 202431 Dec 2025: revenue 407.32M; earnings -62.00M; profit margin -15.22%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$2.88(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$2.88High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning ARDX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-56.10M
Profit margin
-12.44%
Return on assets · 12 month
-10.76%
Index membership
(m)
Employees
489.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
4.14M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-6.35%*
Total return · month
-11.02%*
Total return · quarter
-35.18%*
Total return · half year
-38.14%*
Total return · year to date
-41.85%*
Total return · 1 year
-39.79%*
Total return · 3 years
-16.91%*
Total return · 5 years
164.84%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$450.89M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

ARDELYX, INC. Overview

View more →

(m)

(m)

SEC CIK
1437402
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
34175 ARDENWOOD BLVD., FREMONT, California, 94555, United States
Fiscal year end
1231
Phone
510-745-7047

Similar stocks

Stock NameCountryMarket CapPE Ratio
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Cryoport, Inc. (CYRX)United States$0.881B-21.29
Theravance Biopharma, Inc. (TBPH)$0.885B16.40
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Apnimed, Inc. (APMD)United States$0.899B
GERON CORP (GERN)United States$0.803B-12.14